Definium Therapeutics (DFTX) Income from Continuing Operations (2021 - 2026)
Definium Therapeutics (DFTX) posted quarterly Income from Continuing Operations of 58205928000.0 for Q1 2026, down 191821.42% year-over-year from N/an in Q1 2025, and down 128642.85% quarter-over-quarter from 45211000.0 in Q4 2025.
Powered by 
Analysis
Definium Therapeutics (DFTX) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Income from Continuing Operations for 6 consecutive years, with 58205928000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 191821.42% year-over-year to 58205928000.0; the TTM figure through Mar 2026 stood at 60861851000.0 (down 58428.33% YoY), while the FY2025 annual figure was 31062295000.0, down 632.56% from the prior year.
- Income from Continuing Operations declined to 58205928000.0 in Q1 2026 per DFTX's latest filing, from 45211000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 5127000.0 in Q4 2022 and bottomed at 58205928000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 3596680595.47 across 5 years, with a median of 22012000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 62.53% — and 2026, when it slumped 191821.42%.
- Definium Therapeutics' Income from Continuing Operations stood at 5127000.0 in 2022, then slumped by 322.88% to 21681000.0 in 2023, then tumbled by 37.63% to 29839000.0 in 2024, then sank by 51.52% to 45211000.0 in 2025, then sank by 128642.85% to 58205928000.0 in 2026.
- Business Quant data shows DFTX's Income from Continuing Operations at 58205928000.0 in Q1 2026, 45211000.0 in Q4 2025, and 44707000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Definium Therapeutics | 4.24 Bn | 4.24 Bn | - | -72.72 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -72.72 Mn |
| Mar 31, 2026 | -57.01 Mn |
| Dec 31, 2025 | -45.37 Mn |
| Sep 30, 2025 | -44.71 Mn |
| Jun 30, 2025 | -40.47 Mn |
| Mar 31, 2025 | -30.33 Mn |
| Dec 31, 2024 | -29.84 Mn |
| Sep 30, 2024 | -22.01 Mn |
| Jun 30, 2024 | -21.81 Mn |
| Mar 31, 2024 | -20.98 Mn |
| Dec 31, 2023 | -21.30 Mn |
| Sep 30, 2023 | -20.45 Mn |
| Jun 30, 2023 | -27.87 Mn |
| Mar 31, 2023 | -19.58 Mn |
| Dec 31, 2022 | 2.06 Mn |
| Sep 30, 2022 | -16.49 Mn |
| Jun 30, 2022 | -16.96 Mn |
| Mar 31, 2022 | -18.51 Mn |
| Dec 31, 2021 | 1.80 Mn |
| Sep 30, 2021 | -17.20 Mn |